S
Spectrawave
Diagnosis and treatment of cardiovascular disease through the development of innovative optical diagnostic and therapeutic devices
About Spectrawave
SpectraWAVE operates in the medical technology sector, focusing on enhancing percutaneous coronary intervention (PCI) outcomes through advanced imaging solutions. The company's core product, the HyperVue Imaging System, combines next-generation optical coherence tomography (OCT) with near-infrared spectroscopy (NIRS) to provide high-resolution images of coronary arteries. This technology aids physicians in evaluating morphology, detecting lipid core plaques, optimizing landing zones, determining stent sizing, and assessing post-PCI results. SpectraWAVE serves healthcare providers, particularly cardiologists and medical institutions involved in interventional cardiology. The business model revolves around the sale and distribution of the HyperVue Imaging System and associated catheters, generating revenue through direct sales and potentially through service agreements for ongoing support and maintenance. The market for SpectraWAVE's products includes hospitals, clinics, and specialized cardiac care centers. The company aims to improve clinical decision-making and patient outcomes by providing actionable, high-quality imaging data in a user-friendly format.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2017
- Headquarters
- Waltham, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 27.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
- Technology
- Deep Tech
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Spectrawave.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2025 | $0 | — | Philips | ↗ |
| SERIES BOther financing | Sep 2024 | $50M | $200M | Lumira Ventures · S3 Ventures · Deerfield · SV Health Investors | ↗ |
Growth signals
Latest recorded traffic for Spectrawave is 1.8K monthly website visits, up 81.8% over the last three months. Spectrawave's team declined 54.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Deerfield
Johnson & Johnson Innovation
Lumira Ventures
S3 Ventures
SV Health Investors
Nova Ventures
Other known investors2 additional known investors
Massachusetts General Hospital
Philips
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spectrawave on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spectrawave’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.